AGP Picks
View all

New Mexico Health Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Mexico Health Reporter.

Press releases published on November 16, 2026

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting
MacuMira Receives CE Mark for Its Microcurrent Treatment for Dry AMD
U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults
Former Cross Country Healthcare CEO Bill Grubbs Takes Expanded Role as LUKE Executive Chairman
Dr. Robert Langer, Co-Founder of Moderna, Joins PolarityBio’s Board of Directors
Galectin Therapeutics Reports September 30, 2026 Financial Results and Provides Business Update
ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
BioVie Presents New Biomarker Data Highlighting Biomarker-Defined Endotypes and Neuropeptide Y Response to Bezisterim at the 4th Long COVID International Conference 2026
Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Akebia Enters into Term Loan Facility with Symbiotic Capital Worth Up to $140 Million
Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
NewGen Provides Business Update

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

New Mexico Health Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.